PharmaTelevision - Ernst & Young: The Best Practice for Firms In The Current Climate

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Ernst & Young: The Best Practice for Firms In The Current Climate

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Paul Larsmon talks with Siegfried Bialojan, Head of Global Life Science Centre, Ernst & Young.

Filmed at BIO-Europe 2009, they discuss:

• trends identified over the last year
• the funding crisis balanced with creative deal-making
• how some small biotechs are finding it difficult to survive
• sustainable solutions to survival in the current market
• short-term vs. long-term strategies
• Siegfried's views on the future of healthcare business models

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Trends identified over the last year.

Paul Larsmon:

Hello and welcome to BIO-Europe 2009 here in the Austrian capital of Vienna. With me today is Seigfried Bialojan from Ernst & Young, welcome.

Seigfried Bialojan:

Thank you.

Paul Larsmon:

You've created a number of reports on the healthcare sector of the year, so what sort of trends have you identified here in Vienna?

Seigfried Bialojan:

Well we do this in pharma and biotech particularly also in the medical device area. I think if we talk about trends I think it's an overall theme that we have this convergence, it's very much realized both in the pharma side and the biotech side that it's a good thing to work together, right both in the need for innovation on the pharma side on the one hand and on the other hand of course the need for selling this kind of information and innovation from the biotech side in order to get funding also. So both of these things play together, and I think that's a pretty fruitful collaboration and we will see more of that, I guess.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Seigfried Bialojan

Head of Ernst & Young's Life Science Center in Germany

Dr. Bialojan studied biology and medicine at the University of Heidelberg. He obtained a PhD in Molecular Biology in 1985. He spent 2 years as a post-doc scientist at the German Cancer-Research-Institute Heidelberg. From 1987-1996, he worked in different positions within Biotechnology-Pharma at BASF AG. In 1996, he became director/genomics and member of the Global R&D Management Team at Knoll AG/BASF Pharma. Since 2000 he was heading the eADME-department at the Knoll AG/BASF Pharma with global responsibilities. In June 2001 he joined Ernst & Young as a Senior Industry Specialist Health Sciences. In October 2002, he took over the Industry Leader position in Health Sciences, coordinating EY's German activities in the Health Science Industry. He is heading the Ernst & Young Health Sciences Competence Center in Germany that employs scientists to provide industry expertise and scientific/technological support to all Ernst & Young service projects dealing with Health Science clients. Dr. Bialojan is closely linked to Ernst & Young 's international network as a member of Ernst & Young 's Global Health Science Steering Committee.

Ernst & Young

Ernst & Young ,is also one of the world's Big Four accounting firms (third in revenue behind PricewaterhouseCoopers and Deloitte Touche Tohmatsu, ahead of KPMG). It has some 700 offices providing auditing and accounting services in 140 countries. The firm also provides legal services and services relating to emerging growth companies, human resources issues, and corporate transactions (mergers and acquisitions, IPOs, and the like). Ernst & Young has one of the world's largest tax practices, serving multinational clients that have to comply with multiple local tax laws.